Alternaria keratitis: Clinical presentation and resolution with topical fluconazole or intrastromal voriconazole and topical caspofungin

Cornea

Volumn 28, Issue 1, 2009, Pages 116-119

  Tu, Elmer Y ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alternaria; Caspofungin; Contact lens; Corneal ulcer; Fluconazole; Keratitis; Posaconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CHLORHEXIDINE; FLUCONAZOLE; ITRACONAZOLE; NATAMYCIN; POSACONAZOLE; PREDNISOLONE ACETATE; TRIFLURIDINE; VALACICLOVIR; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN; PYRIMIDINE DERIVATIVE; STEROID; TRIAZOLE DERIVATIVE;

ADULT; AGED; ALTERNARIA; ALTERNARIA KERATITIS; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; KERATOMYCOSIS; MALE; PRIORITY JOURNAL; STEROID THERAPY; SYSTEMIC THERAPY; TREATMENT OUTCOME; VISUAL ACUITY; CATARACT EXTRACTION; CONTACT LENS; CORNEA STROMA; DRUG COMBINATION; EYE INJURY; FUNGAL EYE INFECTION; INJECTION; KERATITIS; MEDICAL RECORD; MICROBIOLOGY; MIDDLE AGED; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; ALTERNARIA; ANTIFUNGAL AGENTS; CATARACT EXTRACTION; CONTACT LENSES; CORNEAL STROMA; DRUG THERAPY, COMBINATION; ECHINOCANDINS; EYE INFECTIONS, FUNGAL; EYE INJURIES; FEMALE; FLUCONAZOLE; HUMANS; INJECTIONS; KERATITIS; MALE; MEDICAL RECORDS; MIDDLE AGED; PYRIMIDINES; STEROIDS; TREATMENT OUTCOME; TRIAZOLES;

EID: 62149146531     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31818225f8     Document Type: Article

References (32)

1. Ando N, Takatori K. Keratomycosis due to Alternaria alternata corneal transplant infection. Mycopathologia. 1987;100:17-22.
2. Arrese JE, Pierard-Franchimont C, Pierard GE. Onychomycosis and keratomycosis caused by Alternaria sp. A bipolar opportunistic infection in a wood-pulp worker on chronic steroid therapy. Am J Dermatopathol. 1996;18:611-613.
3. Azar P, Aquavella JV, Smith RS. Keratomycosis due to an Alternaria species. Am J Ophthalmol. 1975;79:881-882.
4. Barnes SD, Dohlman CH, Durand ML. Fungal colonization and infection in Boston keratoprosthesis. Cornea. 2007;26:9-15.
5. Daniel E, Mathews MS, Chacko S. Alternaria keratomycosis in a lepromatous leprosy patient. Int J Lepr Other Mycobact Dis. 1997;65:492-494.
6. Kocaturk T, Pineda R II, Green LK, et al. Post-LASIK epithelial dendritic defect associated with Alternaria. Cornea. 2007;26:1144-1146.
7. Ozbek Z, Kang S, Sivalingam J, et al. Voriconazole in the management of Alternaria keratitis. Cornea. 2006;25:242-244.
8. Verma K, Vajpayee RB, Titiyal JS, et al. Post-LASIK infectious crystalline keratopathy caused by Alternaria. Cornea. 2005;24:1018-1020.
9. Robertshaw H, Higgins E. Cutaneous infection with Alternaria tenuissima in an immunocompromised patient. Br J Dermatol. 2005;153:1047-1049.
10. Garg P, Gopinathan U, Choudhary K, et al. Keratomycosis: clinical and microbiologic experience with dematiaceous fungi. Ophthalmology. 2000; 107:574-580.
11. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother. 2006;50:917-921.
12. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2001;39:954-958.
13. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50:2009-2015.
14. Xie L, Zhai H, Shi W, et al. Hyphal growth patterns and recurrence of fungal keratitis after lamellar keratoplasty. Ophthalmology. 2007;115: 983-987.
15. Brooks AM, Lazarus MG, Weiner JM. Soft contact lens contamination by Alternaria alternata. Med J Aust. 1984;140:490-491.
16. Chen J, Fraser T, Fisher D, et al. Characteristics of fungal growth in soft contact lenses. Int Contact Lens Clin. 2000;26:84-91.
17. Simmons RB, Buffington JR, Ward M, et al. Morphology and ultrastructure of fungi in extended-wear soft contact lenses. J Clin Microbiol. 1986;24:21-25.
18. Berger ST, Katsev DA, Mondino BJ, et al. Macroscopic pigmentation in a dematiaceous fungal keratitis. Cornea. 1991;10:272-276.
19. Nosanchuk JD, Casadevall A. Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother. 2006;50:3519-3528.
20. Koc AN, Erkilic K, Evrensel N, et al. A case of Alternaria keratitis treated with fluconazole. Eur J Clin Microbiol Infect Dis. 1997;16:322-323.
21. Pujol I, Aguilar C, Gene J, et al. In vitro antifungal susceptibility of Alternaria spp. and Ulocladium spp. J Antimicrob Chemother. 2000;46:337.
22. Ferrer C, Munoz G, Alio JL, et al. Polymerase chain reaction diagnosis in fungal keratitis caused by Alternaria alternata. Am J Ophthalmol. 2002; 133:398-399.
23. Zahra LV, Mallia D, Hardie JG, et al. Case report. Keratomycosis due to Alternaria alternata in a diabetic patient. Mycoses. 2002;45:512-514.
24. Bunya VY, Hammersmith KM, Rapuano CJ, et al. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol. 2007; 143:151-153.
25. McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol. 1998;36:2353-2355.
26. Tu EY, McCartney DL, Beatty RF, et al. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol. 2007;143:222-227.
27. Garcia-Valenzuela E, Song CD. Intracorneal injection of amphothericin B for recurrent fungal keratitis and endophthalmitis. Arch Ophthalmol. 2005;123:1721-1723.
28. Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: an electroret-inographic and histopathologic study. Arch Ophthalmol. 2004;122:1687-1692.
29. Bouyer S, Imbert C, Daniault G, et al. Effect of caspofungin on trophozoites and cysts of three species of Acanthamoeba. J Antimicrob Chemother. 2007;59:122-124.
30. Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother. 1997;41:1835-1836.
31. Kahn JN, Hsu MJ, Racine F, et al. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrob Agents Chemother. 2006;50:2214-2216.
32. Lalitha P, Shapiro BL, Srinivasan M, et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol. 2007;125:789-793.